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ABSTRACT
Canonical transient receptor potential (TRPC) channels are widely expressed 
throughout the nervous system whereas their functions remain largely unclear. Here 
we investigated the effects of TRPC1 deletion on spatial memory ability of mice and the 
potential intervention by environmental enrichment (EE). Significant spatial memory 
impairment assessed by conditional fearing test, Y maze test and step-down test in 
TRPC1 knockout mice was revealed. The behavioral abnormality were attenuated by 
the treatment of EE. Proteomic analysis by two-dimensional fluorescence difference 
gel electrophoresis (2D-DIGE) coupled with a matrix-assisted laser desorption/
ionisation-time of flight (MALDI-TOF) and tandem mass spectrometry (MS) revealed 
that TRPC1 deletion caused differential expression of a total of 10 proteins (8 up-
regulated and 2 down-regulated) in hippocampus. EE treatment resulted in differential 
expression of a total of 22 proteins (2 up-regulated and 20 down-regulated) in 
hippocampus of TRPC1 knockout mice. Among these differentially expressed proteins, 
the expression of a-internexin and glia maturation factor β (GMF-β), two proteins 
shown to impair memory, were significantly down-regulated in hippocampus of TRPC1 
knockout mice by EE treatment. Taken together, these data suggested that TRPC1 
regulated directly or indirectly the expression of multiple proteins, which may be 
crucial for the maintenance of memory ability, and that EE treatment modulated 
spatial memory impairment caused by TRPC1 depletion and the mechanisms may 
involve the modulation of EE on the expression of those dys-regulated proteins such 
as α-internexin and GMF-β in hippocampus.
INTRODUCTION
The transient receptor potential (TRP) superfamily 
of ion channels represents a group of structurally and 
evolutionarily related cation channels composed of 
several groups that include the TRPC (canonical), TRPV 
(vanilloid), TRPM (melastatin), TRPP (polycystin), 
TRPML (mucolipin), and the TRPA (ankyrin) [1]. The 
TRPC1 cation channel was the first mammalian TRP 
channel that was cloned.
The essential role of TRPC1 is its involvement in 
regulating Ca2+ homeostasis. Activation of the G-protein-
coupled receptor (GPCR) in the plasma membrane (PM) 
results in the activation of phospholipase C (PLC) and 
production of inositol 1, 4, 5-trisphosphate (IP3) from 
phosphatidylinositol-4,5-bisphosphate (PIP2) [2]. IP3 
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binds to the IP3 receptor (IP3R) on the endoplasmic 
reticulum (ER) to induce a rapid Ca2+ release from the 
ER [3]. Intracellular Ca2+ is released to extracellular 
space by plasma membrane Ca2+-ATPases and Na+–Ca2+ 
exchangers [4]. The depletion of the internal Ca2+ stores in 
the ER causes activation of store-operated Ca2+ (SOC) entry 
channels [5]. SOC-mediated Ca2+ entry, a critical process 
to maintain ER Ca2+ levels, is dependent on TRPC1. 
After store depletion, TRPC1 interaction with the SOCE 
modulator stromal interaction molecule 1 (STIM1) causes 
Ca2+ influx [5]. TRPC1 knockdown induced cell cycle 
arrest in G0/G1, indicating that SOCE represents a principal 
mechanism regulating the proliferation of adult neural 
progenitor cell (aNPCs) [6]. Ca2+ entry via TRPC1 activated 
the AKT pathway, which has a key role in neuroprotection 
[7]. TRPC1 knockout mice (TRPC1-/-) showed an increased 
unfolded protein response and loss of dopaminergic neurons 
in the substantia nigra, a condition closely resembling 
Parkinson’s disease [7]. Neurons obtained from transgenic 
drosophila models of Huntington’s disease (HD) displayed 
increased store-operated Ca2+ entry, which was suppressed 
by a class of quinazoline-derived compounds. These 
compounds improved the neurodegenerative phenotype of 
HD flies and the effects required the expression of TRPC1 
[8]. These data suggested the physiological and pathogenic 
roles of TRPC1 in the nerve system.
Studies have shown that TRPC1 is widely expressed 
in the ER [9], neuronal dendrites [10], and plasma 
membrane [11]. The expression of TRPC1 protein was 
down-regulated in aorta in 16- to 20-month-old rats 
compared to that from 2-to-4 month-old [12]. The high 
expression of TRPC1 channels in mammalian temporal 
lobe structure suggests that TRPC1 may be involved 
in neuronal plasticity, learning and memory, and also 
contribute to neuronal survival [7, 13]. Although TRPC1 
is highly expressed in hippocampus, whether it is involved 
in hippocampus-dependent memory remains still elusive.
Environmental enrichment (EE) refers to housing 
conditions, where animals could strengthen the senses, 
cognition and movement of the stimulus compared to 
a normal cage environment [14, 15]. EE involves a 
combination of increased social interaction, physical 
exercise and continuous exposure to learning tasks, and 
can increase levels of neurotrophins, such as nerve growth 
factor (NGF), which plays integral roles in neuronal 
signaling [16, 17]. EE was shown to protect against HD, 
Alzheimer’s disease, Down syndrome and stroke [18–21]. 
EE rescued the loss of proteins, such as brain-derived 
neurotrophic factor, dopamine- and cAMP-regulated 
phosphoprotein and cannabinoid receptor 1 in HD [22, 23]. 
EE was also shown to delay the loss of peristriatal cerebral 
volume in R6/2 HD mice [24]. In addition, EE was able to 
decrease Aβ levels and amyloid deposits [25], and increased 
the expression of BDNF, NGF-A and NGF-B as well as 
enhanced dendritic growth in stroke [26–28]. These data 
revealed wide neuroprotective effects via targeting multiple 
critical pathways or molecules in neurological diseases. In 
the present study, we are aimed to explore the effects of 
TRPC1 depletion on spatial memory, and the potential 
invention of EE treatment and the molecular mechanisms.
RESULTS
Spatial memory deficit was caused by TRPC1 
depletion and rescued by EE treatment
Trace cued and contextual fear conditioning: As 
shown in Figure 1a, there were no significant differences 
among the four groups during the first 3 min in the training 
session before the CS-US presentation. A significant 
difference in the proportion of time spent on freezing 
for the last 2 min of the training session was observed 
(P < 0.01). TRPC1-/- mice froze significantly less than 
the WT mice (P < 0.01), indicating that TRPC1 depletion 
caused spatial memory deficit. TRPC1-/- mice treated 
with EE froze significantly more than TRPC1-/- mice (P < 
0.01), indicating that memory deficit was rescued by EE 
treatment. There were no significant differences among the 
groups during the first 2 min in the novel context before 
the CS presentation. TRPC1-/- mice froze significantly less 
than the WT mice (P < 0.05), and TRPC1-/- mice treated 
with EE froze significantly more than TRPC1-/- mice (P < 
0.05) during the 60s auditory cue (Figure 1b).
Lastly, when the mice were returned to the training 
environment for the contextual fear test, a significant 
difference in the proportion of time spent on freezing 
among the groups was observed 48h after the training. 
TRPC1-/- mice froze significantly less than the WT mice 
(P < 0.05), and TRPC1-/- mice treated with EE froze 
significantly more than the TRPC1-/- mice (P < 0.05) 
(Figure 1c). These data indicated that the memory ability 
of TRPC1-/- mice was significantly decreased compared to 
WT mice. The memory ability was significantly enhanced 
in TRPC1-/- mice after treatment of EE.
Y maze test: TRPC1-/- mice showed significantly 
decreased ratio of entry compared with the WT mice 
(P < 0.01) (Figure 2a). TRPC1-/- mice treated with EE 
displayed higher ratio of entry than TRPC1-/- mice (P < 
0.05) (Figure 2a). Compared with the WT mice, the ratio 
of distance for TRPC1-/- mice was significantly decreased 
(P < 0.05) (Figure 2b). However, the ratio of distance 
was significantly increased in TRPC1-/- mice treated with 
EE compared with non-treated TRPC1-/- mice (P < 0.05)
(Figure 2b). There were no significant differences in the 
ratio of time among all the groups (Figure 2c). These data 
suggested that TRPC1 depletion impaired the memory of 
mice and EE treatment could rescue the impairment.
Step-down test: Day 1 was the memory acquisition 
period. No significant differences in latency were observed 
among the groups during day 1 (Figure 3a). The number 
of errors was significantly higher in TRPC1-/- mice 
compared to the WT mice (P < 0.001), and the number of 
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errors was significantly decreased in EE-treated TRPC1-/-  
mice compared to non-treated TRPC1-/- mice (P < 0.05) 
(Figure 3b). These data indicated that TRPC1 depletion 
impaired memory acquisition, and EE treatment could 
prevent the impairment. On Day 2, memory consolidation 
was evaluated. The latency was significantly shorter in 
TRPC1-/- mice compared to the WT mice (P < 0.001), 
and the latency was significantly prolonged in EE-treated 
TRPC1-/- mice compared with non-treated TRPC1-/- mice 
(P < 0.001) (Figure 3c). No significant differences in 
the number of errors were observed among the groups 
during the memory consolidation test (Figure 3d). These 
data further suggested that TRPC1 depletion impaired 
the memory of mice and EE treatment could rescue the 
impairment.
Identification of differentially expressed proteins 
in hippocampus in WT mice and TRPC1-/- mice 
treated with or without EE
To identify the potential molecules involved 
in memory impairment caused by TRPC1 depletion, 
comparative proteomic analysis was performed on the 
brain samples from WT mice and TRPC1-/- mice treated 
with or without EE. Representative 2D-DIGE gel images 
of sample proteins acquired from the WT and TRPC1-/- 
mice treated with or without EE were shown in Figure 
4a-4d, 5a-5d and 6a-6d. The spots showing a fold-change 
of 1.1 or greater and a P-value ≤ 0.05 were considered 
differentially expressed protein spots. Differentially 
expressed proteins were identified and annotated (Figure 
4e, 5e and 6e) in the form of protein ID. The fold-change 
levels and p-values calculated using the DeCyder software 
were shown in Table 1, Table 2 and Table 3, respectively. 
Based on the data obtained from the SwissProt database, 
the gI accession number, the percentage of sequence 
coverage, the theoretical pI, the Mascot scores, and the 
theoretical molecular weight of these proteins were also 
shown in the Table 1, Table 2 and Table 3, respectively. 
The proteins with at least two different peptide sequences 
and multiple peptide hits corresponding to every MS/MS 
event were identified. The MS/MS spectra for two proteins 
implicated in memory function, α-internexin and GMF-β, 
were shown in Supplementary Figures 1 and 2.
Figure 1: Spatial memory ability was measured by trace cued and contextual fear conditioning. a. Proportion time freezing 
during the first 3 min of training before CS-US presentation (Pre-US), and the final 2 min of the training session after CS-US presentations 
(Post-US). b. Freezing behavior in the novel context, 24 h after training during the first 2 min of no CS presentation (Pre-Cue) and 1 min 
of CS presentation (Auditory Cue). c. Freezing behavior 48 h after training, in the same context in which training was carried out on day 
1. Values were expressed as mean +/- SEM.*, ** P < 0.05 and P < 0.01, vs. WT, respectively; #, ##P < 0.05 and P < 0.01, vs. TRPC1-/-, 
respectively. n=8-13 for each group.
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Identification of differentially expressed proteins 
in hippocampus between WT and TRPC1-/- mice
A total of 10 proteins were found to be differentially 
expressed between WT mice and TRPC1-/- mice (Table 
1). Among these proteins, 8 protein spots were up-
regulated in hippocampus in TRPC1-/- mice relative 
to the WT mice and 2 proteins were down-regulated. 
The significantly up-regulated proteins in hippocampus 
included phosphoglycerate mutase 1, serum albumin, 
voltage-dependent anion-selective channel protein 2 
(VDAC 2), ATP synthase subunit alpha, mitochondrial, 
dihydropyrimidinase-related protein 2, serum albumin, 
far upstream element-binding protein 2, and v-type proton 
ATPase catalytic subunit A. The significantly down-
regulated proteins included dihydrolipoyllysine-residue 
acetyltransferase component of pyruvate dehydrogenase 
complex, mitochondrial, and heme-binding protein 1.
The PANTHER classification system revealed that 
these proteins could be classified into several groups 
according to their functional properties. The most dominant 
functions of the identified proteins involved catalytic 
activity (38.5%) followed by transporter activity (23.1%), 
binding (23.1%) and receptor activity (15.4%). These 
proteins could be classified into 6 categories according 
to their biological processes, including metabolic 
process, localization, apoptosis process, cellular process, 
development process and multicellular organismal process. 
Among these differential proteins, far upstream element-
binding protein 2 and VDAC 2 were involved in apoptosis 
process. Phosphoglycerate mutase 1, v-type proton ATPase 
catalytic subunit A and ATP synthase subunit alpha were 
involved in ATP synthesis and glycolysis. Serum albumin 
is an abundant plasma protein. Heme-binding protein 1 is 
a 189 amino acid intracellular tetrapyrrole-binding protein 
that assists in prevention of cellular toxicity by removing 
free porphyrinogens from the cell.
The effects of EE treatment on the expression of 
hippocampal proteins in TRPC1-/- mice
A total of 22 proteins were found to be differentially 
expressed between EE-treated TRPC1-/- mice and non-
treated TRPC1-/- mice (Table 2). Among these proteins, 
2 protein spots were up-regulated in EE-treated TRPC1-/-  
mice relative to non-treated TRPC1-/- mice and 20 
protein spots were down-regulated. The significantly up-
regulated proteins included glyceraldehyde-3-phosphate 
dehydrogenase and glyceraldehyde-3-phosphate 
dehydrogenase. The significantly down-regulated proteins 
Figure 2: Spatial memory performance in the Y maze. a. Ratio of entry, b. Ratio of distance and c. Ratio of time. Values were 
expressed as mean +/- SEM. *, ** P < 0.05 and P < 0.01 vs. WT mice, respectively; # P < 0.05 vs. TRPC1-/- mice. n = 8-10 for each group.
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included ATP synthase subunit beta, mitochondrial, 
dihydropyrimidinase-related protein 2, α-internexin, 
vesicle-fusing ATPase, beta-actin-like protein 2, 
dihydropyrimidinase-related protein 2, serine/ threonine-
protein kinase PAK 1, dihydrolipoyllysine-residue 
acetyltransferase component of pyruvate dehydrogenase 
complex, mitochondrial, aconitate hydratase, 
mitochondrial, coronin-1A, dihydropyrimidinase-
related protein 2, v-type proton ATPase catalytic subunit 
A, glia maturation factor beta, glutaminase kidney 
isoform, mitochondrial, stress-70 protein, mitochondrial, 
aconitate hydratase, mitochondrial hypoxanthine-guanine 
phosphoribosyltransferase, t-complex protein 1 subunit 
beta, v-type proton ATPase catalytic subunit A, and 60 
kDa heat shock protein, mitochondrial.
The PANTHER classification system revealed that 
these proteins could be classified into several groups 
according to their functional properties. The most 
dominant functions of the identified proteins involved 
catalytic activity (47.8%) followed by binding (21.7%), 
receptor activity (8.7%), transporter activity (8.7%), 
structural molecule (8.7%) and enzyme regulator activity 
(4.3%). These proteins could be classified into 8 categories 
according to the biological processes, including metabolic 
process, localization, cellular process, development 
process, multicellular organismal process, response to 
stimulus, cellular component organization or biogenesis and 
biological regulation. Among these proteins, α-internexin 
and GMF-β were two memory-associated proteins. 60 
kDa heat shock protein was a pro-apoptotic protein. ATP 
synthase subunit beta, aconitate hydratase, vesicle-fusing 
ATPase, glutaminase kidney isoform and v-type proton 
ATPase catalytic subunit A were involved in ATP synthesis, 
the TCA cycle and glycolysis, respectively. Stress-70 
protein was involved in oxidative stress. Glyceraldehyde-
3-phosphate dehydrogenase was involved in metabolic 
processes. T-complex protein 1 subunit beta is a subunit of 
the hetero-oligomeric complex CCT (chaperonin containing 
TCP-1) present in the eukaryotic cytosol. Coronin-1A 
is preferentially expressed in hematopoietic cells, and it 
Figure 3: Spatial memory ability was measured by step-down test. a. Latencies on Day 1, b. The number of errors on Day 1, c. 
Latencies on Day 2, d. The number of errors on Day 2. Values were represented as mean +/- SEM. * and ***P < 0.05 and P < 0.001 vs. WT 
mice, respectively; # and ### P < 0.05 and P < 0.001 vs. TRPC1-/- mice, respectively. n=8-10 for each group.
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Figure 4: A representative 2D-DIGE gel image of hippocampal proteins from WT mice and TRPC1-/- mice. Hippocampal 
proteins from WT mice and TRPC1-/- mice were labeled with Cy3 or Cy5 dye, respectively (n =6 for each group). An internal standard 
protein sample (a mixture of all hippocampus samples) was labeled with the Cy2 dye. The CyDye-labeled samples were combined, and 
the proteins were co-separated in the first dimension via IEF in 24 cm pH 3–11 nonlinear IPG strips, followed by separation in the second 
dimension via SDS-PAGE. Spots of interest were manually excised, digested and subjected to identification by MALDI-TOF-MS/MS. a. 
A representative image of hippocampus proteins from TRPC1-/- mice labeled with Cy5 dye. b. A representative image of a 2D-DIGE gel 
showing Cy3-labeled hippocampus proteins from WT mice. c. A representative image of a 2D-DIGE gel showing Cy2-labeled proteins 
as internal standards. d. A merged image of the 2D-DIGE gel displaying Cy2-, Cy3- and Cy5-labeled proteins. e. Greyscale 2D-DIGE 
gel image showing 10 differentially expressed protein spots identified by MALDI-TOF-MS/MS (black numbers with white square) in 
hippocampus of TRPC1-/- mice relative to WT mice.
Oncotarget27861www.impactjournals.com/oncotarget
Figure 5: A representative 2D-DIGE gel image of hippocampal proteins from TRPC1-/- mice treated with or without 
EE. Hippocampal proteins from TRPC1-/- treated with or without EE were labeled with Cy3 or Cy5 dye, respectively (n =6 for each 
group). An internal standard protein sample (a mixture of all hippocampus samples) was labeled with the Cy2 dye. The CyDye-labeled 
samples were combined, and the proteins were co-separated in the first dimension via IEF in 24 cm pH 3–11 nonlinear IPG strips, followed 
by separation in the second dimension via SDS-PAGE. Spots of interest were manually excised, digested and subjected to identification 
by MALDI-TOF-MS/MS. a. A representative image of hippocampus proteins from EE-treated TRPC1-/- mice labeled with Cy5 dye. b. A 
representative image of a 2D-DIGE gel showing Cy3-labeled hippocampus proteins from TRPC1-/- mice. c. A representative image of a 
2D-DIGE gel showing Cy2-labeled proteins as internal standards. d. A merged image of the 2D-DIGE gel displaying Cy2-, Cy3- and Cy5-
labeled proteins. e. Greyscale 2D-DIGE gel image showing 22 differentially expressed protein spots identified by MALDI-TOF-MS/MS 
(black numbers with white square) in hippocampus of EE-treated TRPC1-/- mice relative to non-treated TRPC1-/- mice.
Oncotarget27862www.impactjournals.com/oncotarget
Figure 6: A representative 2D-DIGE gel image of hippocampal proteins of EE-treated WT mice and WT mice. The 
hippocampal samples from EE-treated WT mice and WT mice (n = 6 for each group) were labeled with Cy-Dye, multiplexed, and underwent 
isoelectric focusing on 24 cm pH 3-11 nonlinear IPG strips. The proteins were subsequently separated on large-format 12.5% gels. Spots of 
interest were manually excised, digested and subjected to identification by MALDI-TOF-MS/MS. a. Cy3-labled hippocampus proteins of 
EE-treated WT mice. b. Cy5-labeled hippocampus proteins of WT mice. c. Cy2-labeled proteins as internal standards. d. The merged image 
showing Cy2-, Cy3-, and Cy5-labeled proteins. e. Greyscale 2D-DIGE gel image showing 3 differentially expressed protein spots identified 
by MALDI-TOF-MS/MS (black numbers with white square) in hippocampus of EE-treated WT mice relative to WT mice.
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carries a coiled-coil domain of the leucine zipper variety 
which mediates the formation of homotrimeric complexes 
[29]. The dihydropyrimidinase related protein 2 (DRP-2) 
plays a vital role in the axonal growth and guidance [30].
Identification of differentially expressed proteins 
in hippocampus between EE-treated WT mice 
and non-treated WT mice
A total of 3 protein spots were found to be 
differentially expressed between EE-treated WT mice and 
non-treated WT mice (Table 3). Among these proteins, 2 
protein spots were up-regulated in EE-treated WT mice 
relative to WT mice and 1 protein spots were down-
regulated. The significantly up-regulated hippocampal 
proteins included 26S protease regulatory subunit 7 and 
dihydropyrimidinase-related protein 2. The significantly 
down-regulated proteins was dihydrolipoyllysine-residue 
acetyltransferase component of pyruvate dehydrogenase 
complex, mitochondrial.
PANTHER analysis revealed that these proteins 
were involved in catalytic activity in metabolic process 
according to their functional properties, suggesting that EE 
treatment may exert effects on metabolism in hippocampus 
in WT mice.
Validation of differentially expressed proteins by 
western-blot analysis
To confirm the data by 2D-DIGE, Western-blot 
analysis was performed. Among the differentially 
expressed proteins, two memory-related molecules, 
α-internexin and GMF-β, were selected for validation. A 
trend of up-regulation of both α-internexin and GMF-β 
was shown in hippocampus in TRPC1-/- mice compared 
to the WT mice (Figure 7a-7c), while the treatment of EE 
significantly decreased the expression of both α-internexin 
and GMF-β in TRPC1-/- mice (Figure 7a-7c). These data 
further validated the data by 2D-DIGE.
Table 1: Differentially expressed protein spots in hippocampus between TRPC1-/- and WT mice identified via 
2D-DIGE/MALDI-TOF-MS/MS
Spot No Protein 
ID. a
Accession No. Protein name b
Mascot 
score
Cove. c
(%)
MWd
(Da) PI 
e
TRPC1-/- vs WT
Ratio f P-value
434 34 PGAM1_MOUSE Phosphoglycerate mutase 1 445 18 28928 6.67 1.68 0.003
68 35 ALBU_MOUSE Serum albumin 528 13 70700 5.75 1.19 0.009
85 36 DPYL2_MOUSE Dihydropyrimidinase-related protein 2 482 13 62638 5.95 1.34 0.01
427 37 VDAC2_MOUSE
Voltage-dependent 
anion-selective channel 
protein 2
41 9 32340 7.44 1.12 0.011
69 38 ALBU_MOUSE Serum albumin 539 14 70700 5.75 1.36 0.017
74 31 VATA_MOUSE V-type proton ATPase catalytic subunit A 345 11 68625 5.42 1.14 0.017
489 39 HEBP1_MOUSE Heme-binding protein 1 59 10 21167 5.14 -1.95 0.017
141 41 ATPA_MOUSE ATP synthase subunit alpha, mitochondrial 586 13 59830 9.22 1.16 0.034
93 1 ODP2_MOUSE
Dihydrolipoyllysine-
residue acetyltransferase 
component of pyruvate 
dehydrogenase complex, 
mitochondrial
383 9 68469 8.81 -1.08 0.038
33 42 FUBP2_MOUSE Far upstream element-binding protein 2 206 7 77184 6.9 1.28 0.045
a Protein ID assigned manually. b Protein name identified by MS. c Sequence coverage achieved by MALDI-TOF-MS. 
d Theoretical molecular weight of the protein(s). e Theoretical isoelectrical point of the protein(s). f The ratio in spot density 
from TRPC1-/- mice compared to WT mice. n = 6 for both group.
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Table 2: Differentially expressed protein spots in hippocampus between EE-treated TRPC1-/- mice and non-treated 
TRPC1-/- mice identified via 2D-DIGE/MALDI-TOF-MS/MS
Spot 
No
Protein 
ID. a
Accession No. Protein name b
Mascot 
score
Cove. c
(%)
MWd
(Da) PI 
e
TRPC1-/-+EE vs 
TRPC1-/-
Ratiof P-value
513 5 G3P_MOUSE Glyceraldehyde-3-phosphate dehydrogenase 117 4 36072 8.44 1.54 0.0056
514 6 G3P_MOUSE Glyceraldehyde-3-phosphate dehydrogenase 120 4 36072 8.44 1.64 0.0065
20 7 ATPB_MOUSE ATP synthase subunit beta, mitochondrial 254 10 56265 5.19 -1.5 0.0074
106 8 DPYL2_MOUSE Dihydropyrimidinase-related protein 2 694 17 62638 5.95 -1.1 0.0089
61 9 NSF_MOUSE Vesicle-fusing ATPase 170 6 83131 6.52 -1.3 0.0091
70 10 ACTBL_MOUSE Beta-actin-like protein 2 74 10 42319 5.3 -1.2 0.0092
59 11 DPYL2_MOUSE Dihydropyrimidinase-related protein 2 486 12 62638 5.95 -1.2 0.015
124 14 AINX_MOUSE Alpha-internexin 91 12 55879 5.23 -1.3 0.017
110 13 PAK1_MOUSE Serine/threonine-protein kinase PAK 1 51 3 61041 5.53 -1.3 0.017
115 16 DPYL2_MOUSE Dihydropyrimidinase-related protein 2 617 15 62638 5.95 -1.1 0.022
527 33 GMFB_MOUSE Glia maturation factor beta 137 42 16884 5.08 -1.4 0.023
30 17 ACON_MOUSE Aconitate hydratase, mitochondrial 844 17 86151 8.08 -1.2 0.026
177 19 COR1A_MOUSE Coronin-1A 234 11 51641 6.05 -1.3 0.028
113 18 GLSK_MOUSE Glutaminase kidney isoform, mitochondrial 235 5 74771 8.23 -1.1 0.028
83 20 VATA_MOUSE V-type proton ATPase catalytic subunit A 779 21 68625 5.42 -1.2 0.029
32 21 ACON_MOUSE Aconitate hydratase, mitochondrial 933 17 86151 8.08 -1.2 0.03
90 24 ODP2_MOUSE
Dihydrolipoyllysine-
residue acetyltransferase 
component of pyruvate 
dehydrogenase complex, 
mitochondrial
811 15 68469 8.81 -1.2 0.033
91 27 GRP75_MOUSE Stress-70 protein, mitochondrial 213 6 73768 5.91 -1.2 0.038
160 28 TCPB_MOUSE T-complex protein 1 subunit beta 88 4 57783 5.97 -1.1 0.04
448 30 HPRT_MOUSE Hypoxanthine-guanine phosphoribosyltransferase 134 9 24783 6.21 -1.1 0.041
(Continued )
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TRPC1 depletion caused neuronal loss and 
apoptosis in hippocampus
In order to determine the effects of TRPC1 depletion 
on neuronal survival, we performed immunofluorescence 
staining using neuron-specific marker NeuN and TUNEL 
staining to evaluate the changes of apoptosis in hippocampus. 
The data showed the number of NeuN-positive cells was 
significantly decreased in hippocampal CA1, CA3 and 
dentate gyrus (DG) of TRPC1-/- mice compared to the WT 
mice (P < 0.05) (Figure 8a-8d), while the treatment of EE 
significantly increased the number of NeuN-positive cells in 
TRPC1-/- mice (P < 0.05) (Figure 8a-8d). The data showed 
TUNEL-positive cells were significantly increased in 
hippocampal CA1, CA3 and DG of TRPC1-/- mice relative 
to the WT mice (P < 0.05) (Figure 9a-9d). TUNEL-positive 
cells were significantly decreased in hippocampus of 
TRPC1-/- mice treated with EE compared with non-treated 
TRPC1-/- mice (P < 0.05) (Figure 9a-9d). These data 
suggested that TRPC1 depletion caused neuronal loss and 
apoptosis, and EE treatment could prevented neuronal loss 
and apoptosis in hippocampus of TRPC1-/- mice.
DISUSSION
TRPC1 is highly expressed in hippocampus and 
involved in the regulation of proliferation, indicating 
that TRPC1 may be involved in the process of spatial 
memory [6, 13]. EE was shown to modulate hippocampal-
dependent behavior in rodents [31]. Our study 
demonstrated that TRPC1 depletion caused proteomic 
change in hippocampus and spatial memory impairment, 
and EE could rescue memory impairment caused by 
TRPC1 depletion.
The behavioral tests, i.e. the trace cued and 
contextual fear conditioning, Y maze test and step-down 
test, consistently demonstrated that TRPC1 depletion led 
to spatial memory impairment in mice. The proteomic data 
suggested that TRPC1 regulates directly or indirectly the 
expression of a number of proteins in hippocampus. These 
proteins were involved in metabolic process, localization, 
apoptosis process, cellular process, development process 
and multicellular organismal process. However, neuronal 
apoptosis could cause memory impairment especially in 
regard to the hippocampus [32]. Voltage-dependent anion-
Spot 
No
Protein 
ID. a
Accession No. Protein name b
Mascot 
score
Cove. c
(%)
MWd
(Da) PI 
e
TRPC1-/-+EE vs 
TRPC1-/-
Ratiof P-value
74 31 VATA_MOUSE V-type proton ATPase catalytic subunit A 345 11 68625 5.42 -1.2 0.042
129 32 CH60_MOUSE 60 kDa heat shock protein, mitochondrial 714 17 61088 5.91 -1.2 0.05
a Protein ID assigned manually. b Protein name identified by MS. c Sequence coverage achieved by MALDI-TOF-MS. 
d Theoretical molecular weight of the protein(s). e Theoretical isoelectrical point of the protein(s). f The ratio in spot density 
from EE-treated TRPC1-/- mice compared to TRPC1-/- mice. n = 6 for both group.
Table 3: Differentially expressed protein spots in between EE treated-WT mice and non-treated WT mice identified 
via 2D-DIGE/MALDI-TOF-MS/MS
Spot No Protein 
ID. a
Accession No. Protein name b
Mascot 
score
Cove. c
(%)
MWd
(Da) PI 
e
WT+EE vs WT
Ratiof P-value
93 1 ODP2_MOUSE
Dihydrolipoyllysine-
residue acetyltransferase 
component of pyruvate 
dehydrogenase complex, 
mitochondrial
383 9 68469 8.81 -1.1 0.015
281 2 PRS7_MOUSE 26S protease regulatory subunit 7 124 4 49016 5.72 1.29 0.025
151 4 DPYL2_MOUSE
Dihydropyrimidinase-
related protein 2 460 13 62638 5.95 1.27 0.04
a Protein ID assigned manually. b Protein name identified by MS. c Sequence coverage achieved by MALDI-TOF-MS. 
d Theoretical molecular weight of the protein(s). e Theoretical isoelectrical point of the protein(s). f The ratio in spot density 
from EE-treated WT mice compared to WT mice. n = 6 for both group.
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selective channel protein 2 (VDAC 2) and far upstream 
element-binding protein 2 were apoptosis-related proteins. 
VDAC 2 was a channel associated with cellular apoptosis. 
The recombinant pro-apoptotic proteins Bax and Bak 
were able to accelerate the opening of VDAC, whereas 
the anti-apoptotic protein Bcl-xL closes VDAC by binding 
to it directly [33]. In the present study, the expression 
level of VDAC 2 was significantly higher in TRPC11-/- 
mice compared to WT mice, and the up-regulation was 
prevented by EE treatment in TRPC1-/- mice, suggested 
VDAC 2 could be involved in apoptosis, in turn, memory 
impairment caused by TRPC1 depletion. Based on the 
functional analysis on differentially expressed proteins 
in hippocampus, we speculated that neuronal apoptosis-
related molecule VDAC 2 could be involved in spatial 
memory impairment in TRPC1-/- mice. However, the 
specific roles of this protein in memory deficit in TRPC1-/- 
remain to be further elucidated.
EE was able to facilitate enhanced sensory, 
cognitive and motor stimulation of mice [14, 15], and was 
shown to enhance learning and memory [34, 35] and the 
mechanisms may involve hippocampal neurogenesis [15]. 
In this study, we further demonstrated that EE could rescue 
spatial memory impairment caused by TRPC1 depletion 
as measured by three behavioral tests. Furthermore, we 
also revealed that EE could modulate the expression of 
a number of proteins in hippocampus in TRPC1-/- mice. 
In order to better understand the possible involvement 
of these differentially expressed proteins in amelioration 
of memory impairment in TRPC1-/- mice by EE, in the 
following section, we focused on the discussion of 
differentially expressed proteins associated with memory 
and apoptosis.
Alpha-internexin is a constitutional intermediate 
neurofilament protein first described in 1985 [36]. 
A growing body of evidence has demonstrated that 
α-internexin is involved in neurodegenerative diseases 
associated with neurofilament accumulation and mislocation 
[37]. Transgenic mice overexpressing α-internexin proteins 
displayed dis-organization of the IF network, which could 
cause neurofilament mis-accumulation, progressive 
neurodegeneration, and loss of neurons ultimately [38]. 
Furthermore, overexpression of α-internexin in PC12 cells 
induced apoptosis-like cell death [39]. Our data showed 
a trend of up-regulation of α-internexin in hippocampus 
in TRPC1-/- mice and EE could significantly suppress the 
Figure 7: Verification of α-internexin and GMF-β by Western-blot analysis. a and b. The relative levels of α-internexin in 
hippocampus in WT mice and TRPC1-/- mice treated with or without EE. a and c. The relative levels of GMF-β in WT mice and TRPC1-/- 
mice treated with or without EE. *P < 0.05 versus WT mice, #P < 0.05 versus TRPC1-/- mice. n = 3 for each group. Values were expressed 
as mean +/- SEM.
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Figure 8: TRPC1 depletion caused neuronal loss. a. Immunofluorescent images depicting the number of neurons as evidenced by 
NeuN-staining. b. The number of NeuN-positive cells in CA1. c. The number of NeuN-positive cells in CA3. d. The number of NeuN-
positive cells in DG.* and **P < 0.05 and P < 0.01 vs WT mice, respectively; # and ## P < 0.05 and P < 0.01 vs TRPC1-/- mice, respectively. 
All the values were expressed as mean +/- SEM. n=3 for each group. Scale bar = 100 μm.
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Figure 9: TRPC1 depletion caused hippocampal neuronal apoptosis. a. A representative image of hippocampal neuronal 
apoptosis. b. The number of apoptotic cells in CA1. c. The number of apoptotic cells in CA3. d. The number of apoptotic cells in DG.* and 
**P < 0.05 and P < 0.01 vs WT mice, respectively; # and ##P < 0.05 and P < 0.01 vs TRPC1-/- mice, respectively. All the values were expressed 
as mean +/- SEM. n=3 for each group. Scale bar = 100 μm.
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expression of α-internexin, indicating an involvement of 
α-internexin in memory impairment in TRPC1-/- mice and 
the protective effects of EE on memory.
GMF was shown to activate a number of genes 
related to pro-inflammatory effects in the nervous system, 
such as tumor necrosis factor-α (TNF-α), interleukin 
1-beta (IL-1β), 12-lipoxygenase and chemokine 
CX3C, which were involved in the pathophysiology 
of neurodegenerative disorders such as AD [40]. It was 
reported that the overexpression of GMF in astrocytes 
led to the destruction of primary oligodendrocytes and 
neurons by interactions between highly purified cultures of 
astrocytes, microglia, oligodendrocytes and neurons[41]. 
Besides, it was demonstrated that spatial memory retention 
was improved in GMF knockout mice compared to WT 
controls following Aβ infusion [40]. These data indicated 
crucial roles of GMF in pro-inflammatory responses and 
memory. In this study, we demonstrated a trend of up-
regulation of GMF-β in hippocampus in TRPC1-/- mice 
and EE could significantly down-regulate the expression 
of GMF-β, indicating an involvement of GMF-β in 
memory impairment in TRPC1-/- mice and the protective 
effects of EE against spatial memory deficit as observed.
Heat shock protein-60 was a pro-apoptotic protein, 
which can activate caspase 3 and thus leads to cellular 
apoptosis [42]. Our present study showed that EE could 
down-regulate the expression of heat shock protein-60 
in hippocampus of TRPC1-/- mice, suggesting that the 
protective effects of EE against memory deficit in TRPC1-/- 
mice may also involve the down-regulation of Heat shock 
protein-60.
The dihydropyrimidinase related protein 2 (DRP-
2) is involved in the axonal growth and guidance, and 
its expression was increased in AD brains, suggesting a 
role in impaired neural network formation in AD [30]. 
In the present study, we found that the expression of 
DRP-2 was significantly up-regulated in hippocampus in 
TRPC1-/- mice compared to WT mice, and EE treatment 
prevented the up-regulation of DRP-2 in hippocampus 
in TRPC1-/- mice. It was suggested that dys-regulation 
of DRP-2 in hippocampus may lead to impairment of the 
brain functions such as spatial memory ability, and EE 
treatment could rescue the impairment via modulating 
the expression of DRP-2, as evidenced by modulation of 
DRP-2 expression by EE treatment in TRPC1-/- mice.
In summary, our current data demonstrated that 
TRPC1 depletion altered the expression of a number of 
proteins in hippocampus and spatial memory impairment, 
and that EE treatment could rescue memory deficit caused 
by TRPC1 depletion. These data indicated that TRPC1 
regulated directly or indirectly the expression of multiple 
proteins, which could be crucial for the maintenance 
of spatial memory ability, and that EE treatment could 
prevent spatial memory impairment through its modulation 
effects on the expression of those dys-regulated proteins 
such as α-internexin and GMF-β in hippocampus.
MATERIALS AND METHODS
Animals and treatment protocol
The TRPC1-/- mice were supplied by Prof. Lutz 
Birnbaumer (NIEHS, US) and the control mice were 
purchased from Vital River Laboratory Animal Technology 
Co. Ltd (Beijing, China). All the animal experiments 
were performed according to the “Policies on the Use of 
Animals and Humans in Neuroscience Research” revised 
and approved by the Society for Neuroscience in 1995, 
and all the efforts were made to minimize animal suffering 
to reduce the number of animals used. The mice were kept 
in cages under a 12-hour light/12-hour dark cycle with the 
light on from 7: 00 am to 7:00 pm at stable temperature 
(23–25°C) and humidity. All the mice were housed in 
groups of 10 mice per cage (470×350×200 mm) with free 
access to food and water.
A total of sixty mice at 3 months old were used in 
this study. The WT mice and TRPC1-/- mice were randomly 
divided into four groups: WT mice, EE-treated WT mice, 
TRPC1-/- mice and EE-treated TRPC1-/- mice. The WT and 
TRPC1-/- mice were treated by EE for 6 weeks.
Trace cued and contextual fear conditioning
Trace cued and contextual fear memory is 
hippocampus-dependent memory [43]. Contextual fear 
conditioning consists of an initially neutral conditioned 
stimulus (CS), typically an auditory tone and an 
unconditioned stimulus (US), typically a foot shock. In 
the training session (Day 1), the mice were placed in white 
box and left to explore for 3 min. Tone (20 sec, 75 dB, 
2800 Hz) and foot shock (2 sec, 0.5 mA) were separated 
by a 20-sec trace interval. All the mice received 5 tone-
shock trials and a 200-sec inter-trial interval between CS 
onset and the next CS onset. After the last shock, the mice 
were left for 2 min. The mice were trained in the Freeze 
Monitor environment. Following the training session, 
all the mice were returned to their home cages. Urine 
and feces were cleaned with 75% ethanol after each test 
session to reduce the possibility of odor interference.
The auditory cued fear test sessions were performed 
on day 2, and 24 h after the training, and the mice were 
placed in black box instead of the white box. In order to 
change the smell of the environment, some orange peels 
were put in the black box. The mice was allowed freely to 
explore 2 min. The tone was delivered in the same way as 
on Day 1 during the training, but without foot shock. On 
Day 3, 48 h after the training, the mice were returned to the 
original training room for 60 min before being placed back 
in white box without CS or US for an 8 min context test.
The recognition Y-maze test
Y-maze is a Y-shaped apparatus, with three arms 
(start arm, novel arm and other arm), each 44 cm long 
Oncotarget27870www.impactjournals.com/oncotarget
and 15 cm wide, with walls 10 cm high. The arms are at 
a 120° angle from each other. Three arms were randomly 
designated: start arm, novel arm, and other arm. The start 
arm and other arm were randomly designed to avoid 
the spatial memory error. Urine and feces were cleaned 
with 75% ethanol after each test session to reduce the 
possibility of odor interference.
The Y-maze test consisted of 2 trials separated by 
an inter-trial interval (ITI). During the training phase, the 
novel arms were blocked off, and the mice were allowed 
to explore the start arm and the other arm for 10 min. 60 
min later, the 2nd trial (retention) was conducted. For the 
2nd trial, the mice were placed back in the Y-maze for 5 
min, with all three arms open. Using a ceiling-mounted 
CCD camera, all the trials were recorded on a VCR. 
Video recordings were later analyzed and the number of 
entries, the time spent and the distance traveled in each 
arm were analyzed. Because of their natural curiosity, the 
mice prefer to explore the novel arm. We define the ratio 
of entry as the total entries into the novel arm versus the 
total entries into any arm of the maze, the ratio of time as 
the total time spent in the novel arm versus the total time 
spent in any arm of the maze, the ratio of distance as the 
total distance in the novel arm versus the total distance in 
any arm of the maze. These parameters are indicative of 
spatial recognition memory of the mice.
Step-down test
The training apparatus was a 60 cm × 10 cm× 10 
cm plastic box, the floor of which was made of parallel 
0.1 cm-caliber stainless steel bars spaced 0.5 cm apart. An 
elevated rubber platform (diameter: 10 cm, height: 4.5 cm) 
was placed in the middle of the training box apparatus. 
On the first training day, the mice were first exposed to 
a 5 min learning course, during which they were placed 
on the platform, and then energized (36 V, AC) for 5 min. 
If the animals stepped down from the platform (“error 
trial”), they were punished by an electric foot shock. The 
numbers of “errors” (steps down from the platform) and 
the time for mice to jump on the platform for the first time 
during the training period were recorded. After 24 h, mice 
were placed on the platform, and the numbers of “errors” 
and the time for mice to steps down from the platform for 
the first time were also recorded, which was taken as a 
measure of memory retention.
Sample preparation for 2-D electrophoresis
The mice treated with 6 weeks were sacrificed 
after behavioral tests. The hippocampi were isolated 
on the ice and then stored at −80°C. The brain samples 
were suspended in DIGE-specific lysis buffer (7M urea, 
2M thiourea, 30 mM Tris-HCl, 4% CHAPS, pH 8.5) and 
ultrasonicated for 2 min in cycles of 3s on and 5 s off 
at 35% power using a Fisher 550 Sonic Dismembrator 
(Pittsburgh, PA, USA) until the samples are clarified. The 
samples were incubated on the ice for 30 min, and then 
centrifuged subsequently at 20,000 g at 4°C for 60 min. 
The supernatants were ultrafiltered at 14,000 g at 4°C 
for 30 min to remove salt and other impurities, and then 
resuspended in DIGE-specific lysis buffer. The protein 
solutions were collected and stored at −80°C. The protein 
concentrations were determined by 2-D Quant Kit (GE 
health care, USA) in accordance to the manufacturer’s 
protocol.
DIGE labeling of protein samples
Each CyDye stock was reconstituted in 99.8% 
anhydrous N, N-Dimethylformamide (DMF, Sigma 
227056) to give a final dye concentration of 1 nmol/μL. A 
working solution of 200 pmol/μL of each CyDye used to 
label proteins were generated by dilution of stock solutions 
with DMF. All the samples from WT and TRPC1-/- mice 
were diluted to 5 μg/μL after the protein quantification. A 
pooled internal standard was composed of 5 μL of all the 
samples from WT and TRPC1-/- mice. A dye swap was 
performed to control for preferential labeling by one of the 
dyes or for the different fluorescent characteristics of the 
gel at the different wavelengths. 5 μ of each protein sample 
(25 μg) with a pH of 8.0–9.0 was minimally labeled with 
200 pmol Cy3 (GE Healthcare, 25-8008-61) or Cy5 (GE 
Healthcare, 25-8008-62), and the pooled internal standard 
was labeled with Cy2 (GE Healthcare, 25-8008-62). The 
labeling reaction was incubated on ice in the dark for 30 
min. The reaction was quenched by addition of 10 mM 
lysine (Sigma, L5626) for 10 min at 4°C in the dark. After 
the protein samples were labeled, the Cy2-, Cy3- and Cy5-
labeled samples were mixed together and 80 μL of 2×lysis 
buffer (8 M urea, 2% CHAPS, 0.2% DTT, 2% (v/v) IPG 
buffer, pH 3-11 NL, 0.002% bromophenol blue) was 
added to each mixture and incubated on ice for 10 min in 
the dark. Rehydration buffer was then added to make the 
total volume of the sample up to 450 μL.
2-D Difference gel electrophoresis (2D-DIGE)
The first dimension was performed on Ettan 
IPGphor Isoelectric Focusing System (GE Healthcare). A 
total 75 μg of each labeled samples were put into 24 cm 
pH 3-11 NL Immobiline DryStrips (GE Healthcare). Then 
2 mL of mineral oil was added to cover each strip to reduce 
solvent evaporation. Proteins were taken up into strips by 
active rehydration at 50 V for 18 h. Isoelectric focusing 
(IEF) conditions were step 300 V for 12 h, step 500V for 2 
h, step 1000V for 2 h, gradient 8000 V for 8 h, step 8000V 
for 8 h at 20°C and the temperatures of the room was kept 
at 18°C. Following isoelectric focusing, each strip was 
equilibrated with a reducing equilibration buffer composed 
of 6 M urea, 75 mM Tris-HCl buffer (pH 8.8), 30% (v/v) 
glycerol, 2% (w/v) SDS, and 1% (w/v) DTT for 15 min 
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at room temperature on the shaking table. Subsequently, 
strips were re-equilibration in the same buffer containing 
6 M urea, 75 mM Tris-HCl buffer (pH 8.8), 30% (v/v) 
glycerol, 2% (w/v) SDS, and 4.5% (w/v) IAA. The 
equilibrated strips were loaded on the top of 12.5% SDS-
PAGE gels with 0.5% (w/v) ultralow melting point agarose 
sealing solution (25 mM Tris, 192 mM glycine, 0.1% SDS, 
0.5% (w/v) agarose, 0.002% (w/v) bromophenol blue). 
Electrophoresis was performed using an Ettan DALTsix 
Electrophoresis System (GE Healthcare) and using the 
following conditions: 1 W/gel for 1 h, then 10 W/gel for 
6 h at 15°C in the dark. Following 2-D electrophoresis of 
the DIGE gels, they were immediately scanned using a 
Typhoon TRIO Variable Mode Imager (GE Healthcare). 
Images scanned at 100 μm resolution on the Typhoon 
scanner were cropped to an appropriate field of interest in 
Image Quant. To control for variation in the signal across 
gels, the PMT was set to ensure that the maximum pixel 
intensity of all of the gel images remained within a range 
of 40,000–60,000 pixels.
Image analysis
The DIGE gels in this experiment were analyzed 
using the DeCyder software package (Version 6.5 GE 
Healthcare) to following the manufacturer’s protocol. 
Following confirmation of appropriate spot detection, 
matching, and normalization, spot statistics were 
reviewed. Both DeCyder and Progenesis incorporated the 
use of a Student’s t test to quantify differential expression 
of spots between the experimental groups. The normalized 
volume of a spot is compared across the gels between 
the replicate groups and spots that were found to be 
statistically significant (p≤0.05) were isolated for further 
investigation. The differentially expressed protein spots 
were identified by mass spectrometry.
Spot picking and in-gel digestion
A total of 1 mg of hippocampal protein was used 
to run 2-DE using identical conditions as above. The 
gel was stained with coomassie blue solution (0.12% 
Coomassie Brilliant Blue G-250, 10% phosphoric acid, 
20% ethanol, 10% ammonia sulfate). The protein spots 
exhibiting significant changes (p≤0.05) detected by 
Decyder software analysis were manually excised from 
the Coomassie brilliant bluestained gel and destained 
with 50% acetonitrile in 25 mM ammonium bicarbonate 
followed by dehydration in 100% acetonitrile. After the 
reagents were removed, the gel pieces were digested 
with 0.15 μg of sequencing-grade trypsin (Promega, 
Madison, Wisconsin, USA) in 15 μL digestion buffer 
containing 25 mM ammonium bicarbonate. The mixture 
was incubated overnight at 37°C, then used to mass 
spectrometry.
Mass spectrometry
Protein identification was carried out on AB SCIEX 
MALDI-TOF/TOF 5800 mass spectrometry (Foster City, 
CA, USA). A total of 0.6uL of peptide extract was used for 
the MADL-TOF-MS analysis and crystallized with 0.6 μL 
10 mg/mL α-cyano-4-hydroxycinnamic acid (CHCA) in 
0.1% TFA, 50% acetonitrile (ACN) directly on the target 
and dried at room temperature. The spectra were externally 
calibrated. MASCOT was used for database searching 
against the SwissProt databases (Matrix Science, UK) 
for the mice brain proteins. The search was carried out in 
Mus musculus database and conducted with a tolerance on 
mass measurement of 100 ppm in MS mode and 0.5 Da 
in MS/MS mode. Up to two missed cleavage per peptide 
was allowed. A fixed carbamidomethyl modification was 
taken into account.
Western-blot analysis
To confirm the data by 2D-DIGE, the expression 
of two proteins was further measured by Western-blot 
analysis. Hippocampal proteins from WT mice, TRPC1-/-  
mice with or without EE treatment were extracted by 
using lysis buffer (Beyotime, China) with protease and 
phosphatase inhibitor cocktail (Thermo Scientific, USA). 
The concentration of total proteins was measured by BCA 
protein assay kit (Thermo Scientific, USA). Protein samples 
were mixed with loading buffer (10% v/v) and heated at 
100°C for 5 min, then separated on 12% PAGE gels with 
4% stacking gels and transferred to PVDF membranes. 
Membranes containing the transferred proteins were 
blocked with 5% non-fat milk in TBST (150 mM NaCl, 
10 mM Tris, 0.1% Tween-20, pH 8.0). Then membranes 
were incubated with anti-α-internexin (1: 10000, Abcam, 
ab40758), anti-GMF-β (1:1000, Santa cruz, sc-134347) 
and anti-β-actin (1:1000, Santa cruz, sc-47778) in TBST 
buffer overnight on ice on the shaking table. After washing 
in TBST (4 x10 min), the membranes were incubated 
with a 1:3000 dilution of anti-rabbit or anti-mouse IgG 
HRP secondary antibody diluted in TBST for 1 h. Then 
the membranes were washed in TBST (4×10 min) and 
developed using chemiluminiscence reagents from an ECL 
kit (Pierce). Blots were detected on a phosphorimager and 
analyzed using ImageQuant 1D software.
Immunofluorescence staining and TUNEL assay
Mouse brain tissues were fixed in 4% 
paraformaldehyde for two days and dehydrated in 
ethanol and embedded in paraffin. The coronal mouse 
brain sections were sectioned. After dewaxing and 
rehydration, the sections were treated with 0.01M citrate 
buffer (pH 6.0) with 0.1% Tween-20 at 95–100°C for 
5 min for antigen retrieval. The sections were incubated 
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at 4°C overnight with the primary antibody (NeuN at 
1 : 5000). After washing with PBS, the sections were 
stained with secondary antibody, Alexa Fluor®-488 for 
1 h in the dark, and then stained with DAPI (Beyotime 
Institute of Biotechnology, Haimen, China) for 1 min 
to reveal the nuclei. The sections were examined with a 
laser scanning confocal microscope. For the measurement 
of apoptosis, TUNEL assay was performed using the 
DeadEnd™ Fluorometric TUNEL System as described in 
the instruction provided by the kit. The images were taken 
using a microscope (Olympus 1X51, Tokyo, Japan).
Statistical analysis
The data were expressed as mean +/- standard error 
(SEM) and analyzed using SPSS 18.0 statistical software 
(SPSS Inc. Chicago, Illinois, USA). One-way ANOVA 
was used to determine the different means among the 
groups. The level of significance was set at P < 0.05.
ACKNOWLEDGMENTS
This work was supported by Guangdong Provincial 
Natural Science Foundation (2014A030313715), 
Shenzhen Special Fund Project on Strategic Emerging 
Industry Development (JCYJ20130329103949650) 
and the Upgrade Scheme of Shenzhen Municipal Key 
Laboratory (JCYJ20130408172946974).
CONFLICTS OF INTEREST
All the authors have no conflicts of interest to 
disclose.
REFERENCES
1. Nilius B, Owsianik G, Voets T, Peters JA. Transient 
receptor potential cation channels in disease. Physiological 
reviews. 2007; 87:165-217.
2. Putney JW. Physiological mechanisms of TRPC activation. 
Pflugers Archiv: European journal of physiology. 2005; 
451:29-34.
3. Cahalan MD. STIMulating store-operated Ca(2+) entry. 
Nature cell biology. 2009; 11:669-677.
4. Fasolato C, Innocenti B, Pozzan T. Receptor-activated Ca2+ 
influx: how many mechanisms for how many channels? 
Trends in pharmacological sciences. 1994; 15:77-83.
5. Putney JW, Jr., McKay RR. Capacitative calcium entry 
channels. BioEssays. 1999; 21:38-46.
6. Li M, Chen C, Zhou Z, Xu S, Yu Z. A TRPC1-mediated 
increase in store-operated Ca2+ entry is required for the 
proliferation of adult hippocampal neural progenitor cells. 
Cell calcium. 2012; 51:486-496.
7. Selvaraj S, Sun Y, Watt JA, Wang S, Lei S, Birnbaumer 
L, Singh BB. Neurotoxin-induced ER stress in mouse 
dopaminergic neurons involves downregulation of TRPC1 
and inhibition of AKT/mTOR signaling. The Journal of 
clinical investigation. 2012; 122:1354-1367.
8. Wu J, Shih HP, Vigont V, Hrdlicka L, Diggins L, Singh 
C, Mahoney M, Chesworth R, Shapiro G, Zimina O, 
Chen X, Wu Q, Glushankova L, Ahlijanian M, Koenig G, 
Mozhayeva GN, et al. Neuronal store-operated calcium 
entry pathway as a novel therapeutic target for Huntington's 
disease treatment. Chemistry & biology. 2011; 18:777-793.
9. Alfonso S, Benito O, Alicia S, Angelica Z, Patricia G, 
Diana K, Vaca L. Regulation of the cellular localization and 
function of human transient receptor potential channel 1 by 
other members of the TRPC family. Cell calcium. 2008; 
43:375-387.
10. Martorana A, Giampa C, DeMarch Z, Viscomi MT, 
Patassini S, Sancesario G, Bernardi G, Fusco FR. 
Distribution of TRPC1 receptors in dendrites of rat 
substantia nigra: a confocal and electron microscopy study. 
The European journal of neuroscience. 2006; 24:732-738.
11. Xu SZ, Beech DJ. TrpC1 is a membrane-spanning subunit 
of store-operated Ca(2+) channels in native vascular smooth 
muscle cells. Circulation research. 2001; 88:84-87.
12. Erac Y, Selli C, Kosova B, Akcali KC, Tosun M. 
Expression levels of TRPC1 and TRPC6 ion channels are 
reciprocally altered in aging rat aorta: implications for age-
related vasospastic disorders. Age. 2010; 32:223-230.
13. von Bohlen Und Halbach O, Hinz U, Unsicker K, Egorov 
AV. Distribution of TRPC1 and TRPC5 in medial temporal 
lobe structures of mice. Cell and tissue research. 2005; 
322:201-206.
14. van Praag H, Kempermann G, Gage FH. Neural 
consequences of environmental enrichment. Nature reviews 
Neuroscience. 2000; 1:191-198.
15. Nithianantharajah J, Hannan AJ. Enriched environments, 
experience-dependent plasticity and disorders of the 
nervous system. Nature reviews Neuroscience. 2006; 
7:697-709.
16. Krech D, Rosenzweig MR, Bennett EL. Effects of 
environmental complexity and training on brain chemistry. 
Journal of comparative and physiological psychology. 
1960; 53:509-519.
17. Ickes BR, Pham TM, Sanders LA, Albeck DS, Mohammed 
AH, Granholm AC. Long-term environmental enrichment 
leads to regional increases in neurotrophin levels in rat 
brain. Experimental neurology. 2000; 164:45-52.
18. van Dellen A, Blakemore C, Deacon R, York D, Hannan 
AJ. Delaying the onset of Huntington's in mice. Nature. 
2000; 404:721-722.
19. Arendash GW, Garcia MF, Costa DA, Cracchiolo JR, 
Wefes IM, Potter H. Environmental enrichment improves 
cognition in aged Alzheimer's transgenic mice despite stable 
beta-amyloid deposition. Neuroreport. 2004; 15:1751-1754.
20. Martinez-Cue C, Baamonde C, Lumbreras M, Paz J, Davisson 
MT, Schmidt C, Dierssen M, Florez J. Differential effects of 
Oncotarget27873www.impactjournals.com/oncotarget
environmental enrichment on behavior and learning of male 
and female Ts65Dn mice, a model for Down syndrome. 
Behavioural brain research. 2002; 134:185-200.
21. Hicks RR, Zhang L, Atkinson A, Stevenon M, Veneracion 
M, Seroogy KB. Environmental enrichment attenuates 
cognitive deficits, but does not alter neurotrophin gene 
expression in the hippocampus following lateral fluid 
percussion brain injury. Neuroscience. 2002; 112:631-637.
22. Spires TL, Grote HE, Varshney NK, Cordery PM, van 
Dellen A, Blakemore C, Hannan AJ. Environmental 
enrichment rescues protein deficits in a mouse model 
of Huntington's disease, indicating a possible disease 
mechanism. The Journal of neuroscience. 2004; 
24:2270-2276.
23. Glass M, van Dellen A, Blakemore C, Hannan AJ, Faull RL. 
Delayed onset of Huntington's disease in mice in an enriched 
environment correlates with delayed loss of cannabinoid CB1 
receptors. Neuroscience. 2004; 123:207-212.
24. Hockly E, Cordery PM, Woodman B, Mahal A, van 
Dellen A, Blakemore C, Lewis CM, Hannan AJ, Bates 
GP. Environmental enrichment slows disease progression 
in R6/2 Huntington's disease mice. Annals of neurology. 
2002; 51:235-242.
25. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-
Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, 
Sisodia SS. Environmental enrichment reduces Abeta levels 
and amyloid deposition in transgenic mice. Cell. 2005; 
120:701-713.
26. Gobbo OL, O'Mara SM. Impact of enriched-environment 
housing on brain-derived neurotrophic factor and on 
cognitive performance after a transient global ischemia. 
Behavioural brain research. 2004; 152:231-241.
27. Dahlqvist P, Zhao L, Johansson IM, Mattsson B, Johansson 
BB, Seckl JR, Olsson T. Environmental enrichment alters 
nerve growth factor-induced gene A and glucocorticoid 
receptor messenger RNA expression after middle cerebral 
artery occlusion in rats. Neuroscience. 1999; 93:527-535.
28. Biernaskie J, Corbett D. Enriched rehabilitative training 
promotes improved forelimb motor function and enhanced 
dendritic growth after focal ischemic injury. The Journal of 
neuroscience. 2001; 21:5272-5280.
29. Gatfield J, Albrecht I, Zanolari B, Steinmetz MO, Pieters J. 
Association of the leukocyte plasma membrane with the actin 
cytoskeleton through coiled coil-mediated trimeric coronin 1 
molecules. Molecular biology of the cell. 2005; 16:2786-2798.
30. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, 
Pierce WM, Booze R, Markesbery WR, Butterfield DA. 
Proteomic identification of oxidatively modified proteins 
in Alzheimer's disease brain. Part II: dihydropyrimidinase-
related protein 2, alpha-enolase and heat shock cognate 71. 
Journal of neurochemistry. 2002; 82:1524-1532.
31. Meshi D, Drew MR, Saxe M, Ansorge MS, David D, 
Santarelli L, Malapani C, Moore H, Hen R. Hippocampal 
neurogenesis is not required for behavioral effects of 
environmental enrichment. Nature neuroscience. 2006; 
9:729-731.
32. Maiti P, Singh SB, Mallick B, Muthuraju S, Ilavazhagan 
G. High altitude memory impairment is due to neuronal 
apoptosis in hippocampus, cortex and striatum. Journal of 
chemical neuroanatomy. 2008; 36:227-238.
33. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins 
regulate the release of apoptogenic cytochrome c by the 
mitochondrial channel VDAC. Nature. 1999; 399:483-487.
34. Rampon C, Tang YP, Goodhouse J, Shimizu E, Kyin M, 
Tsien JZ. Enrichment induces structural changes and recovery 
from nonspatial memory deficits in CA1 NMDAR1-knockout 
mice. Nature neuroscience. 2000; 3:238-244.
35. Lee EH, Hsu WL, Ma YL, Lee PJ, Chao CC. Enrichment 
enhances the expression of sgk, a glucocorticoid-induced 
gene, and facilitates spatial learning through glutamate 
AMPA receptor mediation. The European journal of 
neuroscience. 2003; 18:2842-2852.
36. Pachter JS, Liem RK. alpha-Internexin, a 66-kD 
intermediate filament-binding protein from mammalian 
central nervous tissues. The Journal of cell biology. 1985; 
101:1316-1322.
37. Yuan A, Rao MV, Sasaki T, Chen Y, Kumar A, Veeranna, 
Liem RK, Eyer J, Peterson AC, Julien JP, Nixon RA. 
Alpha-internexin is structurally and functionally associated 
with the neurofilament triplet proteins in the mature CNS. 
The Journal of neuroscience. 2006; 26:10006-10019.
38. Ching GY, Chien CL, Flores R, Liem RK. Overexpression 
of alpha-internexin causes abnormal neurofilamentous 
accumulations and motor coordination deficits in transgenic 
mice. The Journal of neuroscience. 1999; 19:2974-2986.
39. Chien CL, Liu TC, Ho CL, Lu KS. Overexpression of 
neuronal intermediate filament protein alpha-internexin 
in PC12 cells. Journal of neuroscience research. 2005; 
80:693-706.
40. Zaheer A, Zaheer S, Thangavel R, Wu Y, Sahu SK, 
Yang B. Glia maturation factor modulates beta-amyloid-
induced glial activation, inflammatory cytokine/chemokine 
production and neuronal damage. Brain research. 2008; 
1208:192-203.
41. Zaheer A, Zaheer S, Sahu SK, Knight S, Khosravi H, 
Mathur SN, Lim R. A novel role of glia maturation factor: 
induction of granulocyte-macrophage colony-stimulating 
factor and pro-inflammatory cytokines. Journal of 
neurochemistry. 2007; 101:364-376.
42. Samali A, Cai J, Zhivotovsky B, Jones DP, Orrenius S. 
Presence of a pre-apoptotic complex of pro-caspase-3, 
Hsp60 and Hsp10 in the mitochondrial fraction of jurkat 
cells. The EMBO journal. 1999; 18:2040-2048.
43. Chen C, Kim JJ, Thompson RF, Tonegawa S. Hippocampal 
lesions impair contextual fear conditioning in two strains of 
mice. Behavioral neuroscience. 1996; 110:1177-1180.
